Prospect: information for the user
Donopa 50%/50% medicinal compressed gas
Nitrous oxide / Oxygen
Read this prospect carefully before starting to use this medication, as it contains important information for you.
1.What is Donopa and for what it is used
2.What you need to know before starting to use Donopa
3.How to use Donopa
4.Possible adverse effects
5.Donopa storage
6.Contents of the package and additional information
Donopa contains a prepared mixture of nitrous oxide (N2O) and oxygen (medical oxygen, O2), with each constituting 50%, and must be used by breathing the gas mixture.
Donopa can be used in adults and children over 1 month old.
Effects of Donopa
The nitrous oxide constitutes 50 % of the gas mixture. Nitrous oxide has an analgesic effect, reduces the sensation of pain, and increases the pain threshold. Nitrous oxide also presents a relaxing and slightly calming effect. These effects are generated by the action of nitrous oxide on signaling substances present in the nervous system
The effect of Donopa is less in children under three years old.
The oxygen concentration at 50 %, which is approximately double that of the ambient air, guarantees a safe oxygen content in the inspired gas.
Donopa should be used
For dental care, in the case of patients who suffer from anxiety.
No use Donopa:
Before using Donopa, you should inform your doctor if you present any of the following symptoms or signs:
Warnings and precautions
Consult your doctor or pharmacist before starting to use Donopaif:
Prolonged or repeated use of nitrous oxide may increase the risk of vitamin B12 deficiency, which may cause damage to the bone marrow or nervous system. Your doctor may perform blood tests before and after treatment to assess the consequences of a possible vitamin B12 deficiency.
You should also inform your doctor if you present any of the following symptoms or signs:
You should breathe normally during inhalation.
Your doctor will decide if Donopa is suitable for you.
Use of Donopa with other medications
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication.
If you are taking more medications that affect the brain or cerebral function, such as benzodiazepines (tranquilizers) or medications of the type of morphine, you should inform your doctor, since Donopa may increase the effects of these medications. In combination with other sedatives or other medications that affect the central nervous system, Donopa increases the risk of adverse effects.
You should also inform your doctor if you are taking medications that contain methotrexate (for example, for rheumatoid arthritis), bleomycin (to treat cancer), nitrofurantoin or similar antibiotics (to treat infections), or amiodarone (to treat heart diseases), since Donopa increases the adverse effects of these medications.
Donopa can be used during pregnancy if it is clinically necessary.
If Donopa is administered for a short period, it is not necessary to interrupt breastfeeding.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Driving and operating machinery
If you have been given Donopa without any other analgesic/sedative, for safety reasons, you should avoid driving, operating machinery, or performing complex tasks until you are fully recovered (at least 30 minutes).
Do not forget to ask your healthcare professional if it is safe for you to drive.
Donopa will always be administered in the presence of personnel familiar with this type of medication. The personnel will ensure that the Donopa supply is suitable for use and that the equipment is properly configured. While using Donopa, you will be monitored to ensure that you are taking the medication safely. Once you have finished using Donopa, you will continue to be monitored by competent personnel until you have recovered.
Follow exactly the medication administration instructions indicated by your doctor.
Your doctor will explain how to use Donopa, how it works, and what effects its use may cause. In case of doubt, ask your doctor.
Donopa is normally inhaled through a face mask connected to a special valve, which means that you will have full control of the gas flow according to your own breathing. The valve will only be open during breathing. Donopa can also be administered through a nasal mask.
Regardless of the mask you use, you must breathe at a normal intensity through the mask.
Once you have finished using Donopa, you must rest and wait until you feel mentally recovered.
Safety Precautions
If you use more Donopa than you should
It is highly unlikely that you will receive an excessive gas supply, since you yourself control the gas flow and the mixture is fixed (it contains 50% nitrous oxide and 50% oxygen).
If you breathe faster than normal and, therefore, receive more nitrous oxide flow than you should with normal breathing, you may feel considerably tired and, to some extent, disoriented. In that case, you must immediately inform the medical personnel and interrupt the medication administration.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication may produce adverse effects, although not all people will experience them.
Frequent(may affect up to 1 in 10 people)
Dizziness, mild headache, euphoria, nausea, and vomiting.
Infrequent(may affect up to 1 in 100 people)
Intense fatigue. Sensation of pressure in the middle ear, if you use Donopa for a prolonged period. This is due to Donopa increasing pressure in the middle ear.
Abdominal swelling, due to Donopa slowly increasing the volume of gas in the intestines.
Unknown Frequency(available data do not allow for estimation of frequency)
Effects on the bone marrow that may cause anemia.
Effects on nervous functions, numbness, and weakness, usually in the legs.
This is due to nitrous oxide affecting the metabolism of vitamin B12and folic acid, thus inhibiting an enzyme: methionine synthase.
Abnormal movements that generally occur after hyperventilation (increase in respiratory rate during inhalation).
Depressed respiration. You may also experience headaches.
Psychiatric effects such as psychosis, confusion, anxiety, or addiction.
Generalized seizures.
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect not listed in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use:www.notificaRAM.es.
By reporting adverse effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date (Exp) that appears on the cartridge label. The expiration date is the last day of the month indicated.
Store between 0 °C and 50 °C. Do not freeze.
If Donopa has been stored at temperatures that are too low, the cartridges must be stored in a horizontal position at a temperature above +10?°C for at least 48 hours before use.
Keep away from flammable products.
Contact with flammable products may cause a fire.
Do not smoke or use open flames near Donopa.
Do not expose the product to intense heat.
If there is a risk of fire, move the cartridge to a safe location.
Keep the cartridge clean, dry, and free of oils and greases.
Keep the cartridge in a closed storage area reserved for medical gases.
Store and transport with valves closed.
Ensure the cartridge has not suffered impacts or falls.
Inhalation of vapors may cause drowsiness and dizziness.
Composition of Donopa
Appearance of Donopa and contents of the container
Donopa is an colourless, odourless and tasteless gas that is administered in a gas cartridge with a valve to control the flow of gas. The cartridges can be made of steel or aluminium.
Pharmaceutical form: compressed medicinal gas.
The top of the gas cartridge is marked in white and blue (oxygen/nitrous oxide). The body of the gas cartridge is white (medicinal gas).
Dimensions of the packaging in litres (135 bar) | 2 | 2,7 | 5 | 10 | 15 | 20 |
Dimensions of the packaging in litres (185 bar) | 2 | 5 |
Only some sizes of packaging may be commercially available.
Marketing authorisation holder:
SOL FRANCE SUCURSAL EN ESPAÑA
Calle Yeso, num. 2
28500 Arganda del Rey - (Madrid)
Spain
Manufacturer
SOL France
ZI des Béthunes
8 Rue du Compas
95310 Saint Ouen l’Aumone
France
This medicinal product is authorised in the member states of the European Economic Area with the following names:
Bélgica: Antafil
Alemania: Donopa
Austria : Donopa
Bulgaria: ??????
Croacia: Donopa
Eslovenia: Donopa
España: Donopa
Grecia: Donopa
Hungría: Donopa
Irlanda: Donopa
Italy: Donopa
Luxemburgo: Antafil
Países Bajos: Donopa
Reino Unido: Donopa
Date of the last review of this leaflet: 11/ 2022
--------------------------------------------------------------------------------------------------------
The following information is intended exclusively for healthcare professionals:
Safety instructions
The administration or repeated exposure to nitrous oxide may cause addiction. Precautions should be taken in the case of healthcare professionals who, due to their work, are exposed to nitrous oxide.
Nitrous oxide should be administered in accordance with local guidelines.
Donopa should only be used in well-ventilated areas and where special equipment is available for evacuating excess gas. High atmospheric concentrations of nitrous oxide can be avoided by using a gas extraction system and ensuring good ventilation. High concentrations of nitrous oxide in the atmosphere can cause adverse health effects in healthcare personnel or other people present in the vicinity. National guidelines exist regarding the concentration of nitrous oxide in the atmosphere, which indicate that these so-called "health-based exposure limits" should not be exceeded, expressed as TWA (time weight averageor average weighted concentration in time), which is the average concentration during a working day, and STEL (short-term exposure limitor short-term exposure limit), which is the average concentration during a shorter exposure period.
These values should not be exceeded to ensure that personnel are not exposed to risks.
After use, the cartridge valve should be closed firmly. The regulator or connection should be depressurised.
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.